MANNKIND CORP Proceeds from Issuance of Debt
MANNKIND CORP (MNKD) reported Proceeds from Issuance of Debt of $325.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfDebt · last filed 2026-02-26
- MANNKIND CORP proceeds from issuance of debt for the quarter ending 2025-12-31 was $250.00M.
- MANNKIND CORP proceeds from issuance of debt for the quarter ending 2014-12-31 was $0.00, a 100.00% decline year-over-year.
- MANNKIND CORP proceeds from issuance of debt for the quarter ending 2013-12-31 was $40.00M.
- MANNKIND CORP proceeds from issuance of debt for fiscal 2025 was $325.00M.
- MANNKIND CORP proceeds from issuance of debt for fiscal 2014 was $40.00M, a 66.53% decline from fiscal 2013.
- MANNKIND CORP proceeds from issuance of debt for fiscal 2013 was $119.50M.
| Period end | Proceeds from Issuance of Debt 3 month | Proceeds from Issuance of Debt 9 month | Proceeds from Issuance of Debt 12 month | Proceeds from Issuance of Debt 275 month | Proceeds from Issuance of Debt 277 month | Proceeds from Issuance of Debt 280 month | Proceeds from Issuance of Debt 283 month |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | $250.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $325.00M 10-K · filed 2026-02-26 | |||||
| 2025-09-30 | $75.00M 10-Q · filed 2025-11-05 | ||||||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $40.00M 10-K · filed 2017-03-16 | |||||
| 2014-09-30 | $40.00M 10-Q · filed 2015-11-09 | $159.50M 10-Q · filed 2014-11-10 | |||||
| 2014-06-30 | $119.50M 10-Q · filed 2014-08-11 | ||||||
| 2014-03-31 | $119.50M 10-Q · filed 2014-05-12 | ||||||
| 2013-12-31 | $40.00M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $119.50M 10-K · filed 2016-03-15 | $119.50M 10-K · filed 2014-03-03 | ||||
| 2013-09-30 | $79.50M 10-Q · filed 2014-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |